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Abstract
While surgery plays a major role in the treatment and potential cure of esophageal cancer, 
esophagectomy continues to have a significant amount of morbidity compared to other 
surgical oncology procedures. Efforts to improve morbidity and mortality from esopha-
gectomy include the Consensus Guidelines for Complications from Esophagectomies, 
Enhanced Recovery after Surgery protocols as well as others. Although we strive to 
improve morbidity and mortality after these surgeries, adverse events still occur. They 
affect not only patient quality of life and increase cost of care for esophageal cancer but 
also have a negative impact on overall cancer survival. This chapter reviews the preven-
tion of adverse outcomes from esophagectomies as well as discusses the management of 
many complications that may occur more common to the operation.
Keywords: esophagectomy complications, prevention of esophagectomy complications, 
management of esophagectomy complications
1. Introduction
Adverse events from esophagectomies directly impact patient quality of life, cancer recur-
rence/survival, hospital costs and resources, as well as require a great deal of energy from 
those managing them [1, 2]. Prevention of surgical complications is of utmost importance; 
however, adverse events from this major surgical procedure still occur, even in high-volume 
centers or experienced hands. Mortality can range from 7 to 9% while morbidity ranges from 
17 to 74% [3]. Prevention, early recognition, and adequate management of complications can 
decrease mortality [4]. While many studies evaluate postoperative morbidity using even ran-
domized methods, randomized studies on the management of postsurgical complications are 
by nature extremely limited.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Selection of the appropriate patient and surgeon
2.1. The optimal patient
Patient optimization and use of appropriate selection criteria are key to minimizing post-
operative morbidity. Unfortunately, those risk factors for the development of esophageal 
cancer may also put patients at an increased risk for postoperative complications. Risk factors 
include age, elevated BMI, ECOG score/functional status, dyspnea, diabetes, chronic obstruc-
tive pulmonary disease, smoking, alkaline phosphatase level elevations, low serum albumin, 
and increased complexity score [5–11]. However, age and performance status continue to be 
the most commonly reported. Neoadjuvant treatments have not been consistently proven to 
be a risk factor. While fibrosis often occurs after chemoradiation, potentially making surgical 
resection more difficult, data showing optimal timing to surgery after neoadjuvant chemora-
diation and its affect on postoperative morbidity are mixed [12].
2.2. How to optimize the patient
Malnutrition has been reported in 57–80% of patients with esophageal cancer [13, 14]. Many 
factors can be attributed to malnutrition prior to surgery and include patient factors, chemo-
therapy, radiation therapy, and tumor-related causes [15]. It is important to recognize that 
even obese patients can suffer from malnutrition. While laboratory values and anthropomet-
ric measurements can be useful, their values can vary and therefore may not be clinically 
relevant. Therefore, a weight loss of greater than 10% for 6 months or 5% for 1 month is 
considered malnourished [16].
For the malnourished patient, preoperative optimization of nutrition through the advice of a 
dietician is key, but other measures should be considered as well if a patient is unable to toler-
ate at least 50–75% of their caloric needs [15]. The preferred intervention should be handled in 
a multidisciplinary setting and be initiated as early as possible. This decreases the amount of 
weight loss, increases chances of completion of neoadjuvant therapies, and decreases hospital 
admissions [17].
Recommendations to maximize oral nutrition intake include dividing daily oral intake into 
five to six small meals where the patient is given enough time to eat, eating only foods with a 
high nutritional content, paying attention to presentation and preparation of meals to make 
food as desirable as possible, enriching meals and drinks and taking advantage of those days 
where the patient feels like eating, modifying the consistency of foods to ease swallowing, pre-
venting fatigue, decreasing the risk of aspiration, eating non-irritating soft and smooth foods at 
room temperature and maintaining oral hygiene for those with mucositis [15]. Patients should 
also be advised to supplement meals with dietary supplements. The preoperative intake of 
combined “immunonutrition” products consisting of arginine, glutamine, polyunsaturated 
omega-3 fatty acids, nucleotides, and antioxidant micronutrients has been shown to decrease 
postoperative infectious complications and length of hospital stay [15, 18, 19].
For those unable to tolerate adequate nutrition, even with optimization and supplementa-
tion, other interventions are needed. These include either stent placement or percutaneous, 
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endoscopic, or surgical placement of feeding gastrostomy or jejunostomy tubes. Esophageal 
stent placement has the benefit of being placed during endoscopic ultrasound, a common 
staging procedure. While it may improve dysphagia in the neoadjuvant setting, chest pain can 
occur and stent migration can be seen in up to 46% of patients [20]. although stent migration 
can be problematic, it is often a sign of tumor response to neoadjuvant therapy, and therefore 
the stent may not always need to be replaced. Other reported complications of stent place-
ment in the neoadjuvant setting include perforation, mediastinitis, bowel perforation from 
migration, tracheo-esophageal fistula, and bleeding [21].
Jejunostomy and gastrostomy tube placement have been proven safe and effective for peri-
operative nutrition. These can be placed in the laparoscopic, open, endoscopic, or even per-
cutaneous settings. Endoscopic placement may be difficult if a patient has a severe malignant 
stricture/obstruction, which is often the case when a patient is suffering from severe malnutri-
tion and unable to pass food or liquids through the site of tumor. Gastrostomy tubes have 
the advantage of bolus feeding, which may improve quality of life. While gastrostomy tube 
placement has been proven to be safe without increasing the risk of postoperative morbidity, 
jejunostomy tube placement is often preferred given the stomach is the preferred organ for a 
neo-esophagus. Jejunostomy tubes are often placed at the time of esophagectomy as well for 
supportive care. However, some data support that the placement of jejunostomy tubes during 
esophagectomy is not always necessary [22–24]. Unfortunately, tube feeds cannot be given in 
boluses with jejunostomy tubes, which, if occurs, can lead to diarrhea and further dehydra-
tion. Patients therefore require an ongoing pump connection for feedings.
Smoking cessation is crucial to improving morbidity from esophagectomy. This may be most 
beneficial if performed greater than 90 days before surgery [25]. Active smoking has also 
been shown to increase recurrence rates of cancer after esophagectomy [26]. Therefore, smok-
ing cessation counseling and supportive programs are necessary when patients are being 
assessed for esophagectomy.
2.3. The optimal surgeon/hospital
When deciding the optimal surgeon, it is important to understand that outcomes depend on 
two major factors: experience and resources. It is well known that with increasing numbers of 
esophagectomies performed, postoperative morbidity and mortality are improved. In addi-
tion, long-term survival can also improve [27]. While data show improved outcomes at higher 
volume centers, this is inconsistent and may depend further on individual surgeon volumes 
and hospital resources [28]. Begg et al. described low-volume hospitals as 1–5 esophagecto-
mies/year, medium volume 6–11 esophagectomies/year, and high-volume centers as those 
performing >11 esophagectomies/year, with an improved mortality with increasing hospital 
volumes [29]. Later, Birkmeyer et al. divided hospital volumes to <2 esophagectomies/year as 
low-volume and high-volume centers as >19 esophagectomies/year [30]. The 2003 Leapfrog 
Group recommended 13 esophagectomies/year as a minimum volume standard [31]. 
However, esophagectomies at mid-volume centers can also be safely performed, especially 
with a two-surgeon approach [32]. Hospital type may also be important where improved 
reoperation rates and mortality are seen when surgery is performed at University centers or 
institutions centralizing esophageal cancer care [33–35].
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Early recognition and treatment of complications appears to be just as important as prevention 
to improve mortality [36]. The recognition of postoperative problems improves with experience, 
making hospital volumes as well as surgeon volumes important. With morbidity rates being high, 
early intervention is of utmost importance to prevent further adverse outcomes or even death. In 
fact, even in low-volume hospitals, mortality may remain low if adequate resources are available 
[28, 37]. Therefore, these surgeries should only be performed at institutions well equipped to 
handle the possible complications [38–40]. Ancillary departments that should be available in the 
postoperative care may include gastroenterology, interventional radiology, cardiology, an astute 
critical care team, and others. Resources readily available and proven to improve complications 
also include nurse-to-patient ratios, where the incidence of pulmonary and infectious complica-
tions was shown to be increased when nurses had more than two patients [41].
2.4. Optimal surgical approach
Tumor location as well as surgeon experience often dictates the type of surgery performed. 
Multiple accepted operative approaches to esophageal carcinoma include Ivor Lewis esopha-
gogastrectomy, McKeown esophagogastrectomy, transhiatal esophagogastrectomy, and 
left transthoracic or thoracoabdominal approaches. Minimally invasive techniques include 
laparoscopic and robotic esophagectomies. While minimally invasive esophagectomies have 
been shown to be safe and effective with equivalent oncologic outcomes, robotic, rather than 
laparoscopic approaches are becoming common [42–44]. However, one should be aware that 
there is a learning curve when a surgeon is transitioning to minimally invasive esophagecto-
mies [45]. Transthoracic esophagectomies include the Ivor Lewis esophagogastrectomy and 
the McKeown esophagogastrectomy. Morbidity varies on the location of the anastomosis 
and if the transthoracic approach was used. While the transthoracic approach may have an 
increased morbidity, it does allow for extended lymphadenectomies to be performed, pos-
sibly increasing long-term survival [10, 46] .
3. Prevention and management of complications
The Esophagectomy Complications Consensus Group (ECCG) is a group of 21 high-volume 
surgeons from 14 countries that compiled a complete list of complications from esophagec-
tomies [3]. These adverse events are separated into pulmonary, cardiac, gastrointestinal, 
urologic, thromboembolic, neurologic/psychiatric, infectious, wound/diaphragm, and others. 
They also aimed to standardize the definitions and reporting of complications since reported 
literature varied depending on adverse reactions and even mortality definitions. These defini-
tions were defined for anastomotic leak, conduit necrosis, chyle leak and vocal cord injury/
palsy. Given the large number of possible complications, this chapter reviews those more 
common or even specific to esophagectomy.
3.1. Atrial fibrillation
Atrial fibrillation can occur in over 20% of patients undergoing esophagectomy, particularly 
when the transthoracic approach is used [47, 48]. Its occurrence unfortunately can result in 
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hemodynamic instability as well as put patients at an increased risk for stroke. Atrial Fibrillation 
may also be an early warning sign for morbidity, especially anastomotic leak [49]. The mecha-
nism and pathophysiology of postoperative atrial fibrillation is incompletely understood, 
although we know predisposing factors include advanced age, coronary artery disease, heart 
failure, hypertension, mitral valve disease, and previous history of atrial fibrillation [50]. One 
randomized, controlled trial showed that the preoperative use of amiodarone via IV infusion 
significantly reduced the incidence of atrial fibrillation; however, no differences were seen 
in median hospital stay, ICU stay, or adverse events [51]. In a study evaluating amiodarone 
administration through the jejunostomy tube postoperatively, there was only a trend towards 
lower occurrence and a shorter length of stay [52]. Beta-blockers should be continued for the 
prevention of atrial fibrillation as well if a patient is already taking them, but may require a 
reduced dose for the prevention of hypotension, especially with epidural anesthesia. Calcium 
channel blockers, particularly diltiazem, can also be used for the prevention of atrial fibrillation 
and may have less effect on blood pressure than other calcium channel blockers or beta-blockers 
[53]. If atrial fibrillation occurs, amiodarone, calcium channel blockers, and beta-blockers are all 
treatments to be considered, depending on the patient’s hemodynamics.
3.2. Respiratory failure/pneumonia/prolonged ventilation
Respiratory complications in patients undergoing esophagectomy can be problematic and are 
often causes of mortality. When patients need to be reintubated, many require bag ventilation 
or positive pressure prior to intubation, which may cause insufflation of the esophagus and 
stomach, placing pressure on the anastomosis or staple lines. For that reason, CPAP is often 
avoided as well. Direct airway visualization during reintubation is also important to prevent 
mechanical injury in case the esophagus is intubated rather than the trachea, especially if a 
cervical anastomosis is performed.
Pneumonia has been shown to significantly increase mortality compared to other complica-
tions, even anastomotic leak [6, 8]. Unfortunately, it can also be the most common postop-
erative complication and cause for respiratory failure and prolonged ventilation [7]. The 
American Thoracic Society and American Infections Diseases Society define pneumonia into 
hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and health-care-
associated pneumonia (HCAP) [54]. The revised Uniform Pneumonia Score aims to define 
pneumonia occurring after esophagectomies and includes temperature, leukocyte count, and 
pulmonary radiographic findings [55]. Prevention, early recognition, and treatment as well as 
correction of causes are key.
Aspiration is a major cause of pneumonia. This occurs more often with a cervical anasto-
mosis, especially with recurrent laryngeal nerve injury. Recurrent laryngeal nerve palsy can 
occur secondary to stretching, thermal injury, or even compression. If occurs, patients may 
suffer from hoarseness as well as pulmonary complications such as dyspnea and aspiration, 
which puts them at an increased risk for pneumonia and reintubation/prolonged ventilation. 
However, recurrent laryngeal nerve injury may not always present as obvious hoarseness, 
as we know from thyroid surgery data, and therefore its occurrence may be underreported. 
The ECCG defines vocal cord injury/palsy as a vocal cord dysfunction postresection where 
confirmation and assessment are achieved by direct examination [3]. There are three types 
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of injuries/palsies that are each further separated into unilateral (A) and bilateral (B): Type 1 
includes a transient injury requiring no therapy, where only dietary modifications are needed; 
Type 2 is an injury requiring elective surgical procedures such as thyroplasty or medialization 
procedures; Type 3 is an injury requiring acute surgical intervention due to aspiration or 
other respiratory issues that include thyroplasty or medialization procedures. Injury to the 
left recurrent laryngeal nerve is most common and is mainly associated with esophagecto-
mies that include cervical anastomoses or dissections, McKeown-type operations. Therefore, 
prevention may include performing thoracic anastomoses or careful dissection and preven-
tion of injury from the above causes. The early recognition of injury and treatment (which 
may include medialization of the vocal fold) may prevent aspiration and pneumonia and 
therefore may be of benefit early in the postoperative course [56, 57].
Other causes of respiratory failure or shortness of breath can include ARDS, cardiac causes, 
pleural effusions, pneumothorax, phrenic nerve injury, or fistula. Other infections can put 
patients at risk for ARDS (acute respiratory distress syndrome), and cardiac causes may also 
result in respiratory failure and need for reintubation. If ARDS occurs, the cause should be 
evaluated, including examining for other infections (urine, leak, etc.). If cardiac in nature, most 
commonly secondary to atrial fibrillation, heart rate control is usually necessary to alleviate 
symptoms. Pleural effusions and pneumothorax are common and can be managed with chest 
tube placement or percutaneous radiologic drainage, depending on the size of the effusion or 
pneumothorax. If effusions occur simultaneously with anastomotic leak, adequate drainage 
should be performed to prevent empyema and life-threatening mediastinitis. While phrenic 
nerve injury is rare, immediate surgical intervention is not always needed. However, patients 
may require tracheostomy placement for pulmonary conditioning. It is also important to 
remember that patients are at an increased risk for deep vein thrombosis and even pulmonary 
embolism. This may occur prior to or even after esophagectomy. Perioperative prophylac-
tic anticoagulation should be administered in the perioperative setting to prevent deep vein 
thrombosis/pulmonary embolism. Tracheoesophageal fistula should also be considered, espe-
cially later in the recovery period or in a complicated postoperative recovery setting.
Impaired lung function is a significant risk factor for pulmonary complications [8]. With pre-
operative chemoradiation, pneumonitis can occur, making patients at an increased risk for 
postoperative respiratory failure and pneumonia [8]. While some degree of inflammation is 
often seen in preoperative imaging, assuring patient lung function has not decompensated 
is prudent. This can often cause delays in surgery; however, allowing the recovery of lung 
function may improve postoperative pulmonary failure.
Consistent with the recommendations of the Enhanced Recovery After Surgery pathways, 
intravenous fluid administration should be minimized to improve time to return of bowel 
function and decrease the length of hospital stay. Excessive fluid administration/fluid over-
load should also be considered in all patients with acute respiratory failure since the admin-
istration of diuretics may quickly improve symptoms.
3.3. Anastomotic leak/conduit necrosis
Anastomotic leak after esophagectomy can be difficult to manage and has a major impact 
on patient quality of life as well as may affect long-term survival [58, 59]. Incidence varies 
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from 5.7 to 14.3% with a higher incidence in cervical anastomoses versus thoracic [60]. The 
International Study Group for Rectal Cancer proposed the verbiage of anastomotic leak as, 
“A defect of the integrity in a surgical joint between two hollow viscera with communication 
between the intraluminal and extraluminal compartments,” which was later validated and 
expanded to the entire gastrointestinal tract [61]. Lerut et al. with the Surgery Infection Study 
Group defined anastomotic leak severity as Type 1, a radiological leak without any clinical 
findings; Type 2 with minor clinical findings of local inflammation (cervical wound) or X-ray 
showed suppressed leak (thoracic anastomosis); Type 3, a major clinical leak with severe 
disruption and sepsis; Type 4, conduit necrosis seen by endoscopic confirmation [62]. The 
Early Complications Consensus Group (ECCG) defined anastomotic leak as a full-thickness 
GI defect involving esophagus, anastomosis, staple line, or conduit, irrespective of the presen-
tation of the method of identification [3]. Type 1 includes a local defect requiring no change in 
therapy or treated medically or with dietary modification. Type 2 is a localized defect requir-
ing interventional but not surgical therapy (interventional radiology drainage, stent or bed-
side opening and packing of incision). Type 3 is a localized defect requiring surgical therapy.
Many patient factors as well as peri- and intraoperative factors can contribute to anastomotic 
leak. Patients at an increased risk for anastomotic leak include those with increased comor-
bidities, advanced pathologic stage, prior esophagogastric surgeries, and active smoking [63]. 
Patient factors can include preoperative malnutrition, diabetes, prolonged hospitalization, 
hypotension, hypoxemia, preoperative chemotherapy, preoperative chemoradiation, and age. 
Technical factors also impacting the rate of anastomotic leak include the location of the anas-
tomosis, surgery type, tension on the anastomosis, the type of anastomosis (hand sewn vs. sta-
pled), arterial and venous insufficiency, excessive bleeding, and surgeon experience. While leak 
incidence may be higher in a single-layer anastomosis, the incidence of stricture may be higher 
in a double-layer anastomosis [64–66]. While data are mixed, the incidence of leak and stricture 
may also be lower with a stapled anastomosis [67, 68]. Postoperative factors may include gastric 
distention, external compression, infection, re-exploration for bleeding, prolonged mechani-
cal ventilation, and continued hypoxemia and hypotension [69]. Technical considerations to 
decrease the rate of anastomotic leak may include anastomotic support with omentum, pleura, 
pericardium, and fat tissue. Prospective randomized studies have shown that omental wrap-
ping of the anastomosis may decrease the rate of leak or even stricture [70, 71].
Diagnosis can be made by clinical suspicion if a patient presents with fevers, leukocytosis, 
empyema, pleural effusion, pneumomediastinum, increased drainage from the chest tube 
(bile or other gastric contents), the presence of enteric bacteria or bacterial culture or tachycar-
dia. The early detection of anastomotic leaks may also include CRP/ESR elevation, an increase 
in procalcitonin level, and leukocytosis extending past the second and fifth postoperative 
days, respectively [72, 73]. While contrast esophagogram can be performed to determine sub-
clinical leaks, caution is advised given the risks of aspiration [4, 74]. A barium swallow can 
be performed to detect an anastomotic leak; however, its sensitivity can be relatively low and 
may often be performed too early to detect [75, 76]. The oral intake of methylene blue may be 
used given it is otherwise nontoxic. CT scan with oral contrast may also be helpful and show 
contrast extravasation as well as concerning areas for infection.
The etiology of the leak is vital to ascertain where patients with conduit tip necrosis or 
complete conduit ischemia may require different interventions. This often requires direct 
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visualization with EGD for conduit evaluation as well as evaluation of the defect size. The 
ECCG defines conduit necrosis into three types, with recommendations for specific treat-
ments: Type 1 includes a focal conduit necrosis that is identified endoscopically, requiring 
only additional monitoring or nonsurgical therapy; Type 2 includes focal conduit necrosis 
that is identified endoscopically and is not associated with free anastomotic or conduit leak. 
Surgical therapy not involving esophageal diversion is performed; Type 3 includes extensive 
conduit necrosis that is treated with conduit resection and diversion [3].
If a leak occurs, source control with drain placement with or without operative interven-
tion remains key to preventing mortality. For this reason, intraoperative drain placement for 
detection and source control is common. Management often is determined by anastomotic 
location; however, mediastinitis can occur with both intrathoracic and cervical anastomoses, 
a possibly fatal diagnosis for which requires close monitoring and rapid evaluation and treat-
ment. Turkyilmaz et al. created algorithms to help guide treatment for anastomotic leak. For 
cervical anastomoses, a limited leak that is clinically occult may be managed with antibiotics, 
dressing changes, and cleansing with oral isotonic fluid. If there is a clinically prominent cervi-
cal leak, antibiotics, opening of the cervical wound, drain placement, nasogastric decompres-
sion, nutritional support, and cleaning are typically needed. For cervical anastomotic leaks 
that have intrathoracic complications and clinical sepsis failing to improve, drain placement, 
stent placement, decortication, resection/diversion or resection/colonic interposition may be 
needed. For thoracic anastomoses, if a contained leak with less than 30% disruption, injection 
with fibrin glue, endoclips, or stents can be used for management. However, if the defect is 
larger, drainage and esophageal stent placement can be performed followed by surgery if 
stent placement and drainage are unsuccessful (can include primary or supporting tissue 
repair). However, if the anastomosis has a greater than 70% disruption, surgery including 
drainage and primary repair should be performed first with esophageal diversion with pos-
sible colonic interposition if unable to be performed [69].
With the use of self-expanding metal stents, endoscopic management alone has become pos-
sible for anastomotic leaks/disruptions. Covered stents can be placed to control the leak, pre-
venting further seeding into the mediastinum for both cervical and thoracic anastomoses. If 
well controlled, oral intake may also be safe. However, stent migration can occur, requiring 
retrieval and replacement [77]. Stent use may be limited in large defects (which may occur 
from conduit necrosis or staple line disruption). It is also important to understand that lumen 
caliber differences between the esophagus and gastric conduit can result in the reflux of gas-
tric contents around the distal aspect of a stent. This unfortunately may not be seen with 
an esophagogram, but rather be noticed with other imaging such as CT after the reflux of 
contrast and gastric contents occur and may be delayed. Therefore, other options for control 
have emerged including endoscopic vacuum-assisted closure devices and may even be more 
effective than stent placement [78–81].
3.4. Fistula
In addition to source control, the awareness and prevention of esophago/gastrotracheal fis-
tula is also necessary. This can occur from infection itself or even the erosion of foreign mate-
rial (stent, staples, etc.) into the trachea. One should be suspicious in patients with frequent 
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uncontrolled coughing, especially after swallowing, or “Ono’s sign” [82]. Workup and diag-
nosis can include an upper gastrointestinal X-ray with oral contrast or even direct visualiza-
tion with esophagoscopy or bronchoscopy. Prevention may include a pleural wrap around 
the anastomosis at the time of original operation or even at the time of reoperation if a leak 
occurs and anastomotic repair is possible. If reoperation is not performed, stent placement 
may help control symptoms and healing [83]. However, distal feeding tube placement and 
resection may be needed. Treatment is necessary to prevent recurring pneumonia.
3.5. Delayed gastric emptying
Delayed or inappropriate gastric emptying can occur secondary to the disruption of vagal 
nerve complexes to the stomach. This can result in delayed emptying of the stomach, which 
affects not only patient quality of life and inability to obtain oral nutrition but also can put 
patients at an increased risk for reflux of gastric contents and even aspiration. The most com-
mon options for the management of the pylorus include pyloromyotomy, pyloroplasty, intra-
pyloric botulinum toxin injection as well as no intervention. While one multicenter study 
showed no significant difference between pyloroplasty, botulinum toxin-injection, and no 
pyloric treatment, one study did show that intra-pyloric botulinum toxin can increase the risk 
of postoperative reflux and increase the use of promotility agents and endoscopic interven-
tions [84, 85]. While delayed gastric emptying can occur anywhere from 10 to 50%, it also can 
be successfully managed with prokinetic agents (75%) and endoscopic dilation [86].
3.6. Chyle leak/chylothorax
With the thoracic duct being the largest lymphatic vessel in the body as well as being located 
in the chest, posterior to the esophagus, injury can occur. Its location, however, often varies. 
The incidence of chyle leak is rather low (1–4%); however, when it occurs, it can be very prob-
lematic [87]. Chyle contains triglycerides in the form of chylomicrons as well as lymphocytes. 
Chyle leaks can result in malnutrition (with continued protein loss), immune compromise, 
hypovolemia, electrolyte abnormalities, hypoalbuminemia, lymphopenia, and infection [88]. 
The ECCG defines a chyle leak into three different types, where output <1 L/day is further 
classified as “A,” and “B” is further classified as >1 L/day [3]. Type 1 leaks can be managed 
with enteric dietary modifications alone. Type 2 can be managed with total parenteral nutri-
tion. Type 3 requires management with interventional or surgical therapy.
Following esophagectomy, drainage from a chest tube of >500 mL/day is suggestive of a chyle 
leak; however, the measurement of chylomicrons or triglycerides is most commonly utilized 
[89]. A measurement of >4% chylomicrons or fluid containing >100–110 mg/dL of triglycer-
ides is typically considered indicative of a chyle leak. Since a chyle leak may present with 
increased serous or even serosanguinous drainage while fasting, a clinical diagnosis can be 
made by the oral intake of cream followed by milky drainage from the chest tube/drains.
Prevention unfortunately is difficult. Selective en masse ligation has been shown to reduce the 
rate of chylothorax [90]. Also, the preoperative oral administration of cream may help iden-
tify the thoracic duct to aid in the prevention of its injury or to identify the thoracic duct for 
prophylactic ligation [91]. The initial management of a chyle leak usually includes drainage as 
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well as TPN and bowel rest. Decreasing oral or enteral fat intake decreases the flow of chyle 
through the leak, possibly allowing spontaneous closure [92]. Long chain fatty acids should 
be avoided with diets supported by high percentages of medium-chain triglycerides since 
they are typically absorbed directly into intestinal cells, bypassing the thoracic duct [87]. If 
conservative management is not successful, surgical intervention may be necessary, especially 
if the fistula is of high output. Aggressive surgical intervention should be performed if chyle 
output is >1.5 L/day for >5–7 days [93]. Surgical intervention includes thoracotomy or thora-
coscopic thoracic duct ligation on the side of the chylothorax. This is usually assisted by the 
preoperative administration of cream or lipophilic dye to help identify the thoracic duct. If 
the leak can be localized, this may be controlled with clips or suture; however, if the leak is 
unclear, ligation of the thoracic duct just cephalad to the aortic hiatus is recommended [94–96]. 
Pleurodesis can also be performed at the time of ligation as well.
Radiologic-guided/percutaneous embolization is becoming more popular, especially for 
patients who are poor operative candidates. This includes lymphangiography followed by 
transabdominal percutaneous needle cannulation, although a retrograde subclavian vein 
approach can be used [97, 98]. Once the cisterna chyli is canalized, a catheter is advanced into 
the thoracic duct and contrast used to identify the leak. Embolization can then be performed. 
Since surgical intervention to ligate the thoracic duct using thoracoscopy or a thoracotomy 
can result in increased morbidity and mortality, thoracic duct embolization has become 
increasingly more popular when conservative management fails.
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